Preventive effects of low-dose dexamethasone for delayed adverse events induced by carboplatin-based combination chemotherapy

Hitoshi Kawazoe, Yoshiharu Takiguchi, Hiroaki Tanaka, Chiaki Doi, Noriyasu Fukuoka, Nobuhiro Kanaji, Shuji Bandoh, Toshihiko Ishida, Hitoshi Houchi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We performed a retrospective study to examine the protective effect of low-dose dexamethasone (DEX) on delayed adverse events induced by carboplatin (CBDCA)-based combination chemotherapy in patients with thoracic tumors. Low-dose DEX (4-8 mg/day) was administered on day 1 and after, in addition to a serotonin 5-HT3 receptor antagonist. The acute adverse events (day 1) were well controlled in the patients with or without co-treatment of DEX. On the other hand, the delayed nausea, emesis, anorexia, and fatigue after day 2 failed to be controlled by 5-HT3 antagonist alone. Co-treatment with DEX significantly suppressed the grade of the delayed adverse events during days 2-10. The mean ratio of complete protection during days 2-10 were significantly higher in the DEX-treated group compared with the non-DEX-treated group. These results reveal that low-dose DEX is a clinically effective treatment for the prevention of delayed adverse events induced by CBDCA-based combination chemotherapy.

Original languageEnglish
Pages (from-to)1001-1006
Number of pages6
JournalYakugaku Zasshi
Volume127
Issue number6
DOIs
Publication statusPublished - 2007 Jun
Externally publishedYes

Keywords

  • Adverse event
  • Carboplatin
  • Chemotherapy
  • Dexamethasone
  • Nausea

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Preventive effects of low-dose dexamethasone for delayed adverse events induced by carboplatin-based combination chemotherapy'. Together they form a unique fingerprint.

Cite this